Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pediatric and adult patients with a diagnosis of ALL or LBL.~2. Have had an allergic reaction to a long-acting E. coli-derived asparaginase OR have silent inactivation.~3. Have 1 or more courses of E. coli-derived asparaginase remaining in his/her treatment plan.~4. Patients must have, in the opinion of the Investigator, fully recovered from their prior allergic reaction to E. coli-derived asparaginase.~Exclusion Criteria:~1. Have previously received asparaginase Erwinia chrysanthemi or JZP-458.~2. Have relapsed ALL or LBL.~3. Are concurrently receiving another investigational agent and/or treated with an investigational device at the same time as JZP-458 (within 48 hours) during Course 1 of JZP-458.~4. Have a history of ≥ Grade 3 pancreatitis.~5. Prior history of asparaginase-associated ≥ Grade 3 hemorrhagic event or asparaginase-associated thrombus requiring anticoagulation therapy, excluding catheter-related thrombotic events.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JZP-458 (Type: EXPERIMENTAL): Part A (IM JZP-458) of the study will have 2 IM cohorts:~* Cohort 1: a JZP-458 repeat dose/confirmatory cohort; a final IM JZP-458 dose level will be selected, and~* Cohort 2: an expansion cohort to confirm the efficacy and safety of the final IM JZP-458 dose level and schedule~Part B (IV JZP-458 Dose Confirmation) will be conducted to define the optimal dose of the IV administration of JZP-458 for further study in ALL/LBL patients as a repeated dose.~Additional courses of JZP-458 (IM or IV depending on patient's allocation at study enrollment) will be administered based on each patient's original treatment plan for as long as the patient derives clinical benefit.

Based on this trial design, predict the completion outcome and termination type (if applicable).